Mediprost

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mediprost

Property Description
Active Ingredient Alprostadil
Pharmacological Class Prostaglandin Analog, Vasodilator
Key Forms Solution for injection, Intraurethral suppository, Topical cream
Origin Synthetic (Chemically identical to natural Prostaglandin E1)
General Purpose Induce localized smooth muscle relaxation and vasodilation

What is Mediprost and What is its Pharmacological Class?

Mediprost is a prescription-only pharmaceutical preparation whose sole active ingredient is Alprostadil. The drug is classified as a Prostaglandin Analog and is formally identified as a potent vasodilator. This classification reflects its core function of causing blood vessels to widen and surrounding muscle tissue to relax.

The formal classification identifies Mediprost (Alprostadil) as a Prostaglandin E1 Agonist, meaning it mimics the function of the natural substance Prostaglandin E1 (PGE1) within the body. This mechanism is clinically recognized for its direct action on smooth muscle tone and is included in the anatomical therapeutic chemical (ATC) classification system under the Vasoactive substances group.

Alprostadil: Composition and Origin

Alprostadil is a synthetic prostaglandin E1 analog chemically identical to the naturally occurring fatty acid, Prostaglandin E1 (PGE1). As a single active ingredient product, Mediprost is not an extract or a complex combination drug. Its specific chemical formula, C20H34O5, demonstrates its established chemical structure.

To accommodate different therapeutic needs and sites of action, Alprostadil is manufactured in several distinct pharmaceutical preparations. These forms include a powder for solution for injection (for intracavernosal or intravenous (IV) infusion routes), an intraurethral suppository (pellet), and a specially formulated topical cream.

The General Purpose of This Potent Vasodilator

The general purpose of Mediprost (Alprostadil) is rooted in its ability to induce strong smooth muscle relaxation and resultant vasodilation in targeted anatomical areas. This physiological action is essential for specific therapeutic applications in two distinct groups: the adult male population and critically ill neonates.

By acting as a potent vasodilator, the medication facilitates the expansion of blood vessels, maximizing blood flow to promote the engorgement of certain tissues. Alprostadil is used for maintaining the temporary openness of the ductus arteriosus (DA) in neonates with ductal-dependent congenital heart defects.

Regulatory References

  1. Alprostadil Urogenital: MedlinePlus Drug Information
  2. FDA Drug Label for Alprostadil Neonate Indications

What side effects are possible with Mediprost?

The documented safety profile of Mediprost (Alprostadil) is highly dependent on the route of administration, with official adverse reactions categorized by frequency and the body system affected, as established by major regulatory bodies.

Adverse Reaction Classifications

Category Examples from Regulatory Documentation
Very Common Pain at the administration site (e.g., penile pain, injection site pain); Pyrexia (fever) in neonates.
Common Headache, dizziness, mild hypotension (low blood pressure), penile fibrosis, and ecchymosis (bruising) at the injection site.
Uncommon Prolonged erection (Priapism), syncope (fainting), testicular pain.

Official labels group adverse reactions by System-Organ Class (SOC), including Reproductive System disorders (penile pain, fibrosis), Vascular Disorders (hypotension, flushing), and Nervous System Disorders (headache, dizziness).

Serious Adverse Reactions and Safety Constraints

Official government documents define certain events as serious safety concerns:

  • Priapism: A serious and time-critical event defined as a prolonged erection lasting four hours or longer.
  • Penile Fibrosis: The development of fibrotic tissue or plaques, which is officially associated with long-term exposure to the injectable formulation.
  • Neonatal-Specific Serious Events: For intravenous infusion in neonates, life-threatening events such as apnea (cessation of breathing) and cardiac arrest are documented risks.

The medicine is contraindicated in men with pre-existing conditions that predispose to Priapism, such as sickle cell trait/disease, multiple myeloma, or leukemia, as well as those with anatomical penile deformation. The risk of penile fibrosis requires periodic physical examination as a safety measure. The specialized intravenous use in neonates mandates continuous cardiorespiratory monitoring due to the high risk of serious cardiorespiratory adverse events.

Overdose and Emergency Response

Overdose and when to seek help

Mediprost overdose manifestations represent an exaggeration of the drug's potent vasoactive effects, as documented in regulatory labeling. Systemic overdose commonly presents as severe hypotension (low blood pressure), often accompanied by signs of systemic shock, including dizziness, syncope (fainting), flushing, and disturbances in heart rate such as tachycardia or bradycardia. These severe presentations require immediate medical attention.


The official regulatory documents state that no specific antidote is known for Alprostadil overdose. Management focuses on symptomatic and supportive treatment to maintain cardiovascular function, including patient repositioning (Trendelenburg position) and administering a fluid challenge to counteract hypotension.


For localized formulations, overdose is characterized by the time-critical complication of prolonged erection or priapism. Urgent medical consultation is required if an erection persists beyond the four-to-six-hour limit specified in the product labeling, as failure to act can lead to severe tissue damage. The labeling also notes that overdose with the intravenous formulation in neonates carries a specific risk of apnea and seizures, mandating immediate cessation of the infusion and specialized respiratory care.

Therapeutic Uses of Mediprost

What Mediprost Treats: Main Uses and Benefits

The primary therapeutic domain of the active substance in Mediprost is applied in the management of gastrointestinal irritation and symptoms related to inflammatory or irritative states of the stomach lining. The medication is used to help with the management of gastrointestinal discomfort often associated with certain necessary long-term therapies. This is particularly relevant for easing discomfort in patients who are at high risk of experiencing symptoms that create noticeable physiological strain.

The compound is relevant for easing symptom clusters that may become intense or disruptive in conditions presenting with systemic or localized discomfort. It is applied in addressing situations where patients experience heightened physiological activity that can interfere with daily comfort. The medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms, specifically addressing those symptoms related to physical discomfort.

“The compound plays a role in managing symptoms linked to organ-specific functional stress, supporting general well-being during symptomatic phases.”

It is considered relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily.

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Eligibility and Restrictions for Use

This section explains, based solely on authoritative governmental regulatory documents, the patient populations for whom Mediprost is restricted or absolutely prohibited.

Populations Who Must Not Use Mediprost (Contraindications)

Mediprost is contraindicated, meaning its use is strictly prohibited for safety reasons, in the following patient groups:

  • Hypersensitivity: Patients who have a known allergy or severe sensitivity to the active substance of Mediprost or any of its non-active components (excipients).
  • Severe Cardiac Disease: Patients with specific severe, pre-existing heart conditions, including cardiogenic shock, decompensated heart failure, or severe bradycardia or heart block (greater than first-degree) who do not have a functional pacemaker.
  • Severe Pulmonary Disease: Patients with severe, uncontrolled bronchospastic disease, such as severe bronchial asthma.
  • Pregnancy: The use of Mediprost during pregnancy is contraindicated.

Eligibility-Related Restrictions

Age and Physiological Status:

  • Pediatric Patients: Safety and effectiveness have not been established in patients under 18 years of age; the medicine is not indicated for this population.
  • Lactation: Use while breastfeeding is generally not recommended.
  • Renal/Hepatic Impairment: Use in patients with severe hepatic impairment or severe renal impairment is not recommended due to limited data or potential for increased risk, requiring special consideration or restriction.

What should I know about interactions with other medicines?

The official regulatory profile for Mediprost is structured around documented pharmacodynamic interactions affecting the vascular and coagulation systems.

Co-administration of Mediprost with other medicinal products for the treatment of erectile dysfunction is not recommended or contraindicated by official labeling. This includes other vasoactive agents, such as PDE5 inhibitors. This restriction is due to the documented risk of additive effects, potentially leading to prolonged erection and systemic hypotension.

Mediprost may enhance the effects of antihypertensive agents and other vasodilative medicines, a documented pharmacodynamic interaction that increases the risk of hypotension. Similarly, co-administration with anticoagulants or platelet aggregation inhibitors may enhance their action, officially increasing the local risk of bleeding at the administration site.

Regulatory information explicitly states that the potential for pharmacokinetic drug-drug interactions (involving metabolic enzymes) has not been formally studied for the approved administration routes. A specific caution is also noted regarding the excipient Benzyl Alcohol in some formulations and its potential for accumulation in patients with hepatic or renal impairment.

Mechanism of Action

How Mediprost Works

Mediprost (Alprostadil) functions through a precise molecular cascade that results in the modulation of smooth muscle contractility and localized vasodilation.


Prostaglandin Receptor Agonism on Smooth Muscle

Alprostadil acts as a direct agonist at specific Prostanoid Receptors (EP₂ and EP₄) found on the surface of smooth muscle cells. This binding event mimics the body's natural signaling mechanism, rapidly activating the receptor and initiating the subsequent intracellular process.


Intracellular Cyclic AMP (cAMP) Signaling Cascade

Receptor activation triggers the Adenylate Cyclase/cAMP pathway, leading to a surge in the intracellular second messenger, cyclic AMP (cAMP). This signal cascade ultimately causes a rapid reduction in the intracellular calcium ( Ca^2+) required for muscle contraction, resulting in relaxation of the smooth muscle tissue.


Localized Hemodynamic Modulation

The cellular relaxation culminates in localized vasodilation, meaning the targeted blood vessels widen. This physiological change maximizes the local blood flow and perfusion to the specific tissue where the mechanism is engaged, resulting in local adjustments in tissue hemodynamics.

Dosage and Administration Information

Mediprost (Alprostadil) is administered through distinct routes, requiring careful adherence to instructions for dose and frequency based on the patient population. The medicine is supplied in multiple forms, including lyophilized powder that requires reconstitution prior to use and is administered via intracavernosal injection, or as an intraurethral pellet or topical cream for localized adult use. Systemic use for critical pediatric care is managed via continuous IV infusion.

Dosing and Schedule

Patient Population Route of Administration Standard Dosing Rules Maximum Frequency
Adult Male (Localized Use) Intracavernosal injection Initial doses are low, starting at 1.25 mcg or 2.5 mcg, and are gradually titrated by a healthcare provider to determine the lowest effective maintenance dose. Doses greater than 60 mcg are not recommended. No more than three times per week, with a minimum interval of 24 hours between administrations.
Pediatric (IV Infusion) Continuous Intravenous (IV) Infusion Initial infusion rate is typically 0.05 mcg/kg/min to 0.1 mcg/kg/min. The dose must be reduced to the lowest effective maintenance rate (e.g., 0.01 mcg/kg/min) once a therapeutic response is observed. Continuous infusion for the duration required by the clinical protocol.

Administration Requirements

A mandatory procedural condition for all localized forms is that the first administration must be conducted in the healthcare provider's office. This supervision is required for dose determination and training on the self-administration technique. The injectable solution must be clear and colorless, and the injection site should be alternated to ensure proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes research that explored Drug X (Mediprost). Studies evaluated whether Drug X is associated with changes in markers related to inflammation and pain in participants with Condition A.


Clinical Effectiveness and Outcomes

Clinical trials have explored Drug X as a potential treatment for Condition A.

Symptom Management

  • Monotherapy Trials: Studies have examined Drug X alone in participants with Condition A. Researchers investigated whether Drug X was associated with changes in pain scores and daily functioning reported by participants over a 12-week period. Studies noted variation in the time to symptom change.
  • Duration of Treatment: Research has examined whether the duration of treatment is associated with outcomes. One study evaluated the time to symptom change and the change in symptom scores over time.

Combination Studies

  • Drug X and Treatment B: A large Phase 3 study investigated whether the combination of Drug X and Treatment B was associated with a change in the severity of flare-ups. The study evaluated the frequency of these events over one year.
  • Comparison with Other Treatments: Comparative studies have explored whether Drug X and older treatments like Drug Y differed in outcomes related to long-term management. Evidence from direct comparative trials remains sparse concerning various treatment types.

Safety and Tolerability Profile

Safety data were collected across study participants.

  • Observed Side Effects: The most commonly reported side effects across trials included fatigue, headache, and mild digestive upset. The data collection focused on the frequency and severity of these events.
  • Liver Function: Researchers noted specific observations regarding liver function in participants during the study. The study protocols included routine monitoring of relevant blood markers.
  • Long-Term Data: Research is ongoing to evaluate the long-term safety profile of Drug X beyond the initial one-year trial period.

Frequently Asked Questions (FAQ)

Common questions about Mediprost (FAQ)


Q: How long can a person safely stay on Mediprost?

Official regulatory documents do not define a specific maximum duration for the use of Mediprost. However, long-term exposure to the injectable formulation is associated with the risk of penile fibrosis (the development of scar tissue). Because of this documented risk, regulatory profiles require that patients using the injectable form undergo periodic physical examinations as a safety measure.


Q: Are there any common foods or drinks that interact with Mediprost?

According to official product information, there are no known interactions between Mediprost and common foods or non-alcoholic drinks. Standard regulatory guidance states that the drug's action is not generally affected by food intake.


Q: Is it okay to take Mediprost with other prescription drugs?

Regulatory guidance emphasizes that Mediprost is strictly contraindicated (prohibited) with other medicines used for erectile dysfunction. Caution is also noted regarding the co-administration with other medicines that lower blood pressure (antihypertensive agents) or those that prevent blood clotting (anticoagulants). Interactions with other general prescription drugs have not been formally studied for the approved routes.


Q: Can I take vitamins or herbal supplements with Mediprost?

Official patient guidance indicates that patients should inform their healthcare provider about all prescription and over-the-counter medicines they use. This includes all vitamins, minerals, and herbal products before starting or continuing treatment with Mediprost.


Q: Can older adults use Mediprost without special precautions?

No specific adverse events have been documented solely in the geriatric (older adult) population. However, older patients may be more likely to experience age-related issues, such as kidney impairment. Caution is described in regulatory documents for patients with severe renal impairment (kidney issues).


Q: What should I do if I notice a side effect that is not listed on the label?

Patient information sheets consistently describe that all adverse events and side effects are required to be reported to a healthcare provider. This includes any effects that are not listed in the official product label.


Q: Can Mediprost be cut or crushed?

Mediprost is supplied only as a solution for injection or as an intraurethral pellet. The product is not supplied in a standard tablet or capsule form intended to be cut, split, or crushed. Instructions for use require that the pellet form be inserted whole and the injectable solution be used once after reconstitution.


Q: How quickly does Mediprost leave the system if I stop taking it?

According to the pharmacokinetics (the study of how a drug moves through the body), the active ingredient is very rapidly metabolized (broken down). The major circulating breakdown product returns to pre-dose levels within approximately 60 minutes after administration.


Q: Does Mediprost have a generic or cheaper version?

The active ingredient, Alprostadil, is available as a lower-cost generic product in some jurisdictions. However, certain brand-name formulations of the medicine may not have a generic equivalent, depending on the route of administration and manufacturing specifics.


Q: How long does it usually take to see or feel a difference with Mediprost?

For its localized adult uses, official product information indicates that an effect may be observed relatively quickly. This typically occurs within approximately 5 to 20 minutes after injection or 5 to 10 minutes after using the urethral pellet.


Q: Can Mediprost be used by women, or is it only for men?

For its use in adults, the product information specifically describes administration and use only in the adult male population. The safety and effectiveness of the localized formulations have not been established for its use in adult women.


Q: Do I need to take Mediprost at a specific time of day?

Regulatory guidance for the localized forms emphasizes frequency limits, such as a minimum interval of 24 hours between administrations, and a maximum of three times per week. The official instructions do not mandate a specific time of day for administration relative to a patient's schedule.


Q: Can Mediprost affect my ability to drive or operate machinery?

Official patient information notes that Mediprost may cause side effects such as dizziness, lightheadedness, and fainting. Driving a car or operating machinery is not recommended after using the drug until the patient is aware of how the medication affects them.


Q: Will Mediprost affect my blood pressure?

Yes, Mediprost is officially classified as a potent vasodilator, meaning it widens blood vessels. This action can cause mild hypotension (low blood pressure) as a common adverse reaction. It may also enhance the effects of other medicines taken to lower blood pressure.


Q: Are there different strengths of Mediprost available?

Yes, Mediprost is supplied in multiple strengths, which vary depending on the specific formulation and route of administration. For example, the injection is supplied in various dosage sizes such as 5 mcg, 10 mcg, 20 mcg, and 40 mcg vials.


Q: Can you drink alcohol while taking Mediprost?

Official patient guidance indicates that the consumption of alcohol should be discussed with a healthcare professional. Alcohol may potentially decrease the effectiveness of the medication and may also increase the risk of dizziness or fainting.


Q: What is the evidence like for Mediprost's effectiveness?

Data from clinical trials indicate that effectiveness was observed in a majority of subjects following individualized dose titration. Studies have reported varying degrees of success across different formulations, and the documented effectiveness is included in the product label.


Q: Is Mediprost known to cause any skin reactions or rashes?

Yes, rashes and other localized application-site reactions have been reported in clinical studies, particularly with the non-injectable forms. These reactions can include local effects like burning or erythema (redness).


Q: Does Mediprost interfere with cold or flu medications?

The official regulatory label does not list specific interactions with common cold or flu preparations. However, regulatory standards describe the requirement that the use of all over-the-counter (OTC) medicines, including cold and flu preparations, be discussed with a healthcare provider.


Q: Are there different names or brands for the same active ingredient as Mediprost?

Yes, the active ingredient Alprostadil is marketed under several different brand names for its various formulations and routes of administration across different regulatory regions. Mediprost is one name for the product containing Alprostadil.


Q: Is Mediprost a drug that needs to be monitored long-term?

Yes, regulatory information mandates a periodic physical examination as a specific safety measure for patients using the injectable form to check for the development of penile fibrosis. Other safety elements, such as blood pressure, may also be monitored.


Q: What are the common reasons why people stop taking Mediprost?

Data from clinical trials indicate that patient discontinuation often occurs for two main reasons. These include a reported lack of effectiveness or the experience of certain side effects, such as injection site pain, bleeding, or issues with responsiveness to the drug.


Q: Do studies show that Mediprost helps with quality of life?

Clinical trials have included specific outcome measures to evaluate the effect of the medication on aspects related to quality of life. Standardized tools, such as the International Index of Erectile Function (IIEF), have been used by researchers to evaluate symptom changes and daily functioning.


Q: Are there any specific laboratory tests required before starting Mediprost?

While regulatory documentation emphasizes the importance of a physical examination and comprehensive medical history review before starting treatment, it does not explicitly mandate specific pre-treatment laboratory tests for all patients.


How should Mediprost be stored and disposed of?

The required storage conditions for Mediprost (Alprostadil) vary by specific formulation, but are strictly defined in regulatory documents to ensure stability.

Item Official Regulatory Requirement
Storage Temperature The injection powder should be stored at 20 C to 25 C (Controlled Room Temperature). The suppository form requires refrigeration (2 C to 8 C), with limited room temperature storage (e.g., up to 14 days) permitted.
Handling/Protection Do not freeze the product. Store in the original container, away from excessive heat, moisture, and light. The reconstituted solution must not be shaken.
Stability after Mixing The reconstituted injection solution is for single use only. Any unused portion must be discarded after 24 hours from mixing.
Disposal The medication must be kept out of the sight and reach of children. Used needles, syringes, and vials must be placed in an FDA-cleared sharps disposal container immediately. Unused or expired medication must be disposed of according to local regulations or a pharmaceutical take-back program.

These instructions define mandatory temperature ranges, prohibit freezing, and require the safe disposal of all injection materials and unused product as pharmaceutical waste, in accordance with regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mediprost found in:

A-Z Index: